Inc.

View All

Diabetic Peripheral Neuropathy Market
Paradigm Shift In The Diabetic Peripheral Neuropathy Market Landscape As The Focus Shifts Towards The Cure

Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% by 2030 attributed to increasing DPN prevalence, and introduction to gene therapies in the pipeline. Diabetes prevalence has been on a gradual rise globally attributable to a paralleled rise in a sedentary lifestyle, obesity and inc...

Find More

Diabetic-Peripheral-Neuropathy
How are Diabetic Peripheral Neuropathy medications changing the DPN market scenario?

Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030 Diabetic Peripheral Neuropathy (DPN) or Distal Symmetric Polyneuropathy (DSPN) is peripheral nerve dysfunction and damage in diabetic patients. It is a chiefly sensory neuropathy with autonomic nervo...

Find More

Anaphylaxis
Anaphylaxis: A Rare Disease

Anaphylaxis is a rare disease which can even result in life-threatening situations. Mostly the allergic reaction is due to food, insect stings, medications and latex.  Usually, the symptoms are expressed in one part of the body; however, in some instances, the reaction is severe. Sometimes, a specific type ...

Find More

Raynaud's disease
Raynaud’s Disease -A debilitating condition

Raynaud's Disease (RD), also called Raynaud's phenomenon, is a rare disorder of the blood vessels. The symptoms include when one is feeling cold or feeling stressed in some areas of the body like fingers and toes, blood can't reach to the epidermis (surface of the skin) and the affected areas turn wh...

Find More

Delveinsight
Allergic Conjunctivitis (AC) – Common disorder with increasing prevalence

Allergic Conjunctivitis (AC) is a common eye disorder characterized by the inflammation in the tissue that lines the inside of eyelid and outside of the eyeball called conjunctiva. It usually happens when a person’s eyes come into contact with an allergen, a substance that makes the body’s immune system to overreact...

Find More

Delveinsight
Celecoxib first Generic Approval to Teva and Mylan from FDA

On May 30, 2014, the U.S. Food and Drug Administration approved the first generic versions of Celebrex (celecoxib) capsules. Teva Pharmaceutical Industries received approval to market celecoxib capsules in 50 milligram, 100 mg, 200 mg, and 400 mg strengths, and has 180-day exclusivity on the 100 mg, 200 mg, and 400 ...

Find More